[HTML][HTML] Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the …
V Cento, CF Perno - Journal of Global Antimicrobial Resistance, 2020 - Elsevier
Objectives In the HIV-1-positive population, a paradigm shift from three-drug regimens
(3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment …
(3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment …
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review
I Perez-Valero, D Corona, N Martinez… - Expert Review of Anti …, 2023 - Taylor & Francis
Introduction Second-generation integrase strand transfer inhibitors such as bictegravir (BIC)
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …
[HTML][HTML] Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis
R Bai, S Lv, H Wu, L Dai - BMC infectious diseases, 2022 - Springer
Background Global antiretroviral therapy has entered a new era. Integrase strand transfer
inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) …
inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) …
[HTML][HTML] No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV
JE Burns, OT Stirrup, D Dunn, I Runcie-Unger… - Aids, 2020 - journals.lww.com
Objective: Excessive weight gain has been reported with integrase strand transfer inhibitors
(INSTIs). We evaluated weight changes in virologically suppressed adults with HIV who …
(INSTIs). We evaluated weight changes in virologically suppressed adults with HIV who …
Durability of dolutegravir-based regimens: a 5-year prospective observational study
L Taramasso, A De Vito, ED Ricci… - AIDS Patient Care …, 2021 - liebertpub.com
This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along
5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people …
5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people …
[HTML][HTML] Closing the HIV treatment gap for adolescents in Windhoek, Namibia: a retrospective analysis of predictors of viral non-suppression
FK Munyayi, B van Wyk - … Journal of Environmental Research and Public …, 2022 - mdpi.com
Windhoek joined the Fast-Track Cities Initiative in 2017 to optimize HIV service delivery for
adolescents, promoting adherence and sustaining viral suppression. Recent surveys and …
adolescents, promoting adherence and sustaining viral suppression. Recent surveys and …
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
A D'arminio Monforte, A Tavelli, M Sala… - Journal of …, 2023 - academic.oup.com
Objectives To compare the long-term risk of treatment failure of dolutegravir-based ART in
men and women in a real-life setting. Patients and methods Persons living with HIV (PLWH) …
men and women in a real-life setting. Patients and methods Persons living with HIV (PLWH) …
[HTML][HTML] High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria
O Abudiore, I Amamilo, J Campbell, W Eigege… - Plos one, 2023 - journals.plos.org
Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in
2017. However, there is limited documented experience using DTG in sub-Saharan Africa …
2017. However, there is limited documented experience using DTG in sub-Saharan Africa …
Transitioning to dolutegravir in a programmatic setting: Virological outcomes and associated factors among treatment-naïve patients with HIV-1 in the Kilombero and …
AJ Ntamatungiro, A Eichenberger… - Open forum …, 2023 - academic.oup.com
Background Virological outcome data after programmatic transition from non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
[HTML][HTML] Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study
CE Frola, I Aristegui, MI Figueroa, PD Radusky… - PLoS …, 2023 - journals.plos.org
In Argentina, transgender women (TGW) have a high HIV prevalence (34%). However, this
population shows lower levels of adherence, retention in HIV care and viral suppression …
population shows lower levels of adherence, retention in HIV care and viral suppression …